Lightair Ab · NGM:LAIR
Lightair Ab — Biolight International — Investor Presentation (May 2004)
37 slides from Lightair Ab's investor presentation, May 2004
Slide 1: Company presentation May 2004
® Company presentation May 2004
Slide 2: Content
Klicka här för att ändra format Content ® 1. Biolight – the method ® 2. Biolight – how it contributes to hospital care? ® 3. Biolight – areas of application 4. Biolight International AB 5. Financial information Appendix A. Owner structure, Board of Directors and Management ®
Slide 3: 1. The method
Klicka här för att ändra format 1. The method ®
Slide 4: The Biolight method: pulsed monochromatic light
The Biolight method utilizes the biophysical effects Klicka här för att ändra format of pulsed monochromatic light (electromagnetic energy) in different combinations of •Wavelength •Amount of energy and strength •Pulsation •Area of application Monochromatic light 400-700 nm Blått UV ----------------
Slide 5: Clinical effects
Clinical effects • Klicka här Faster healing för att ändra format • Pain relief • Reduced swelling Other • No side effects • Non-invasive • Documented effects – In-vitro studies… – …clinical phase III • CE-marked • Patent protected ® 1. Biolight® – the method
Slide 6: A portable and programmable device
• Klicka A portablehär för att device and programmable ändra format that provides emitting light and energy. • The energy is applied on the patient with a specifically developed diode (total instrument area 60 cm2) • Biolight® Care Devices • Biolight® Biocards (treatment cards) • Biolight® vitamins-
Slide 7: Quality assurance and registration
Klicka här för att ändra format Quality Annex II MDD, ISO 13485:2003 Assurance MDD/93/42/EEC Registration FDA/510(k)/PCD ® 1. Biolight® – the method
Slide 8: Patent applications and approvals by country
Land Ansökta 1996 1997 1998 1999 2000 2001 2002 2003 Totalt Klicka här för att ändra format Sweden US 9 9 2 2 2 2 2 1 3 7 4 Canada 9 2 2 China 9 1 1 2 Germany 9 2 2 France 9 2 2 Switzerland 9 2 2 Austria 9 2 2 Belgium 9 2 2 Denmark 9 2 2 Spain 9 2 2 UK 9 2 2 Ireland 9 2 2 Italy 9 2 2 Netherlands 9 2
Slide 9: 2. How it contributes to hospital care?
Klicka här för att ändra format 2. How it contributes to hospital care? ®
Slide 10: Problems related to inflammatory conditions
Klicka här för att ändra format Problems related to inflammatory conditions? 1. Risk areas of complications • Open wounds, diabetic wounds,… • Infections • Loosening tooth conditions • Systemic diseases 2. Pain and discomfort for patients • Sick leave • Incapable to work 3. Demanding medical treatme
Slide 11: Infections, wounds, pain
Klicka här för att ändra 1. Infections, wounds, pain,… format • Risk for multi resistant bacterial spread? • Pain and discomfort? 89% of patients with pain (Ch Lindberg, KI) • Need for pharmaceutical treatment? • Surgical treatment? • Pain killers? • Risk for patient to become addicted? • Need for r
Slide 12: Traditional treatment methods
Klicka här förtreatment 3. Traditional att ändra format methods • Pharmaceutical treatment • Pain killers – Drug dependence? – Drug dependence? – Side effects? – Side effects? – High costs? • Traditional wound treatment • Invasive treatment/Surgery – Isolates and protects wounds? – Extended sick lea
Slide 13: The ultimate treatment method
Klicka här för att ändra format The ultimate treatment method • Shortens healing and treatment time • Pain reliving • Non addictive • No side effects • Non invasive • Easy to use and cost effective Will contribute to cost cuttings and improved quality! ® 2. Biolight® – how it contributes?
Slide 14: Biolight advantages and disadvantages
® Klicka härBiolight för att ändra format Advantages Disadvantages • Active healing of wounds and other • Unknown method inflammatory conditions • Challenges well established • Reduces pain techniques • No side effects • Perceived as additional treatment time initially • Non invasive • All indicatio
Slide 15: Problems solved with Biolight
Klicka här för att ändra format Problems solved with Biolight® • Reduced risks for infections and complications! • Reduced pain during healing period! • Shortened time for rehabilitation! • Minimized risks for side effects! • Reduced costs for treatment! ® 2. Biolight® – how it contributes?
Slide 16: 3. Areas of application
Klicka här för att ändra format 3. Areas of application ®
Slide 17: Inflammatory conditions: areas of application
Inflammatory conditions Klicka • Wounds här för att ändra format – Geriatric wounds – Diabetic wounds • Acute burns • Surgical wounds – After plastic surgery – Hip joints – Oral surgery • Inflammations caused by unsuitable working postures – Inflammatory conditions and injuries within sport • Period
Slide 18: 4. Biolight International AB
Klicka här för att ändra format 4. Biolight International AB ®
Slide 19: Business concept
Biolight Klicka International här för att ändra AB format Business concept To supply healthcare providers with a light treatment method that catalyses the body's ability to heal wounds and other inflammatory conditions, thereby accelerating and facilitating the healing process as well as shortening
Slide 20: Vision
Biolight Klicka International här för att ändra AB format Vision The Company's long-term vision is to become a leading supplier of light treatment methods. Methods that are very much in demand because they contribute considerably to a more effective treatment of wounds and other inflammatory conditi
Slide 21: Business goals 2004
Biolight Klicka International här för att ändra AB format Business goals 2004 • Carefully establish the acceptance of the method with at least 20 clinics that routinely use the method because of its financial benefits • Identify at least 5 influential opinion leaders who are willing to become ambass
Slide 22: Strategies/activities to achieve the goals
Biolight Klicka här International för att ändra AB format Strategies/activities to achieve the goals • Supply the wound care sector and other application areas with cost effective treatment programs • Establish the method among leading Swedish clinical institutions/opinion leaders • Find proof for t
Slide 23: Market introduction sales process: barriers
Biolight International AB Klicka här Market för attandändra introduction sales process format Barriers against frequent use: • Clinical teams within the wound care sector are rather enthusiastic but have generally not reached a routine use of the method. • Reasons; – In general they have access to o
Slide 24: Market introduction sales process: steps
Biolight International AB Klicka här Market för attandändra introduction sales process format The market introduction will be carried out step wise: 1. Penetrate the Swedish micro market within the wound care sector 2. Eliminate barriers against frequent use 3. Investigate and show the economical ad
Slide 25: Target groups during 2004
Biolight Klicka International härTarget för att ändra AB format groups during 2004 • Opinion leading specialist clinical centers • Clinical centers within the wound care sector • Geriatric care, surgical centers, general hospital care • Rehabilitation and physiotherapeutic centers • Periodontal and
Slide 26: Phase 2 objectives; end 2005
Biolight International AB Klicka härPhaseför att ändra 2 –Objectives; end 2005 format • Finalize Phase 1 with meetings including all clinical users. These meetings make it possible for users to share ideas and experiences as well as reaching a consensus about Biolight as the treatment of choice in w
Slide 27: 5. Financial information
Klicka här för att ändra format 5. Financial information ®
Slide 28: Financial Data (MSEK)
Financial Klicka här Data format för att ändra (MSEK) Income Statement 1998 1999 2000 2001 2002 2003 Net Sales 0,8 0,9 0,5 1,2 1,8 1,3 EBIT -10,1 -14,3 -17,6 -27,0 -24,6 -18,7 Net Profit/Loss -13,5 -13,6 -19,7 -26,4 -25,8 -19,0______ Balance Sheet 1998 1999 2000 2001 2002 2003 Fixed assets 2,9 2,5 2
Slide 29: Economical and financial goals
Economical Klicka här för and att financial ändra goals format From August 2004 • Secure financial withstanding until end of 2005 • Significant sales increase every half year • Significantly improved profitability every half year ®
Slide 30: Appendix
Klicka här för att ändra format Appendix ®
Slide 31: A. Owner structure, Board of Directors and Management
Klicka här för att ändra format A. Owner structure, Board of Directors and Management ®
Slide 32: Owner structure
Owner structure Klicka här Biolight’s för owners ten largest att ändra per 1 Januaryformat 2004 Name/ in order of ownership % of votes % of capital Skagsudde 41,6% 20,8% Thiberg Rolf incl. fam. 8,1% 2,9% Banque Generale Du Luxembourg 7,5% 13,8% BNP Paribas 4,1% 2,2% Banco Teknik & Innovationsfond 3,
Slide 33: Board of Directors
Board Klicka här förofatt Directors ändra format Hans Larsson (Chairman) Chairman since 1995. Chairman of the Board of Nobia AB and Sydsvenska Kemi AB. Board member of, inter alia, Carema AB, Holmen AB, Pergo AB and Svenska Handelsbanken AB. Shareholding: 47,250 B shares. 25% shareholding in major o
Slide 34: Board of Directors, cont'd
Board Klicka härofför Directors, cont’d att ändra format Birgit Gidlund Larsson Board member since 1995. CEO of Skagsudde AB. Board member of Citymail AB and of the Center for Structural Biochemistry at the Karolinska Institute. Shareholding: 37,500 B shares. 25% shareholding in major owner Skagsudd
Slide 35: Scientific Council
Scientific Klicka här för attCouncil ändra format Prof. Jan-Åke Gustafsson (Chairman) Head of the Department of Medical Nutrition and the Department of Biosciences, Novum, Karolinska Institute. Member of the Medical Nobel Assembly at the Karolinska Institute, the Royal Swedish Academy of Sciences an
Slide 36: Management
Klicka härManagement för att ändra format Claes Holmberg, PhD, President and CEO 1980 – 86 Chalmers University of Technology Department of Theoretical Physics, PhD 1985 – 86 Ericson Radar Electronics Project Manager 1986 – 95 Nobel Biocare AB Executive Vice President 1996 – 03 MediTeam Dental AB and
Slide 37: Management, cont'd
Klicka Management, cont’d format här för att ändra Pär Olausson, B.Sc. in Mech. Eng., Manager product development, product supply and quality assurance 2001 – Biolight 2000 – 01 Integration Partner AB Project Leader Carmel Pharma AB 1996 - 00 Manager QA & Production Hans Johansson, Product Manager 1
Biolight International — Investor Presentation (May 2004) on 6ix